Yiwen Zhang

Prof. Yiwen Zhang


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2022 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
MWMengling Wu
Mengling Wu
QHQianrui Huang
Qianrui Huang
YXYao Xie
Yao Xie
XWXuyi Wu
Xuyi Wu
HMHongbo Ma
Hongbo Ma
YXYong Xia
Yong Xia
Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certain cancers, lack of known biomarkers, immune-related toxicity, innate and acquired drug resistance, etc. Overcoming these limitations would significantly expand the anticancer applications of PD-1/PD-L1 blockade and improve the response rate and survival time of cancer patients. In the present review, we first illustrate the biological mechanisms of the PD-1/PD-L1 immune checkpoints and their role in the healthy immune system as well as in the tumor microenvironment (TME). The PD-1/PD-L1 pathway inhibits the anticancer effect of T cells in the TME, which in turn regulates the expression levels of PD-1 and PD-L1 through multiple mechanisms. Several strategies have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including combination therapy with other standard treatments, such as chemotherapy, radiotherapy, targeted therapy, anti-angiogenic therapy, other immunotherapies and even diet control. Downregulation of PD-L1 expression in the TME via pharmacological or gene regulation methods improves the efficacy of anti-PD-1/PD-L1 treatment. Surprisingly, recent preclinical studies have shown that upregulation of PD-L1 in the TME also improves the response and efficacy of immune checkpoint blockade. Immunotherapy is a promising anticancer strategy that provides novel insight into clinical applications. This review aims to guide the development of more effective and less toxic anti-PD-1/PD-L1 immunotherapies.

1 January 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YWYijie Wang
Yijie Wang
JHJun He
Jun He
MLMengya Liao
Mengya Liao
MHMingxing Hu
Mingxing Hu
WLWenzhen Li
Wenzhen Li
LOLiang Ouyang
Liang Ouyang

16 July 2022 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
QHQianrui Huang
Qianrui Huang
MWMengling Wu
Mengling Wu
XWXuyi Wu
Xuyi Wu
YZYiwen Zhang
Yiwen Zhang
YXYong Xia
Yong Xia

1 December 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HZHongjia Zhang
Hongjia Zhang
LBLan Bai
Lan Bai
JHJun He
Jun He
LZLei Zhong
Lei Zhong
XDXingmei Duan
Xingmei Duan
JSJianyou Shi
Jianyou Shi

13 September 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YXYong Xia
Yong Xia
CJChengsen Jia
Chengsen Jia
QXQiang Xue
Qiang Xue
JJJinrui Jiang
Jinrui Jiang
YXYao Xie
Yao Xie
TYTinghong Ye
Tinghong Ye
Repurposing existing drugs for cancer treatment is an effective strategy. An approved antipsychotic drug, trifluoperazine (TFP), has been reported to have potential anticancer effects against several cancer types. Here, we investigated the effect and molecular mechanism of TFP in colorectal cancer (CRC). In vitro studies showed that TFP induced G0/G1 cell cycle arrest to dramatically inhibit CRC cell proliferation through downregulating cyclin-dependent kinase (CDK) 2, CDK4, cyclin D1, and cyclin E and upregulating p27. TFP also induced apoptosis, decreased mitochondrial membrane potential, and increased reactive oxygen species levels in CRC cells, indicating that TFP induced mitochondria-mediated intrinsic apoptosis. Importantly, TFP significantly suppressed tumor growth in two CRC subcutaneous tumor models without side effects. Interestingly, TFP treatment increased the expression levels of programmed death-1 ligand 1 (PD-L1) in CRC cells and programmed death-1 (PD-1) in tumor-infiltrating CD4+ and CD8+ T cells, implying that the combination of TFP with an immune checkpoint inhibitor, such as an anti-PD-L1 or anti-PD-1 antibody, might have synergistic anticancer effects. Taken together, our study signifies that TFP is a novel treatment strategy for CRC and indicates the potential for using the combination treatment of TFP and immune checkpoint blockade to increase antitumor efficiency.

17 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
AZAn-Qi Zeng
An-Qi Zeng
YYYan Yu
Yan Yu
YYYu-Qin Yao
Yu-Qin Yao
FYFang-Fang Yang
Fang-Fang Yang
MLMengya Liao
Mengya Liao
YWYu-Quan Wei
Yu-Quan Wei
Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models Betulinic acid impairs metastasis and reduces immunosuppressive cells in breast cancer models